Aclarion (NASDAQ:ACON – Get Free Report) released its earnings results on Thursday. The company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.21, FiscalAI reports. Aclarion had a negative net margin of 10,948.81% and a negative return on equity of 59.34%. The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.03 million.
Aclarion Price Performance
ACON stock opened at $1.66 on Friday. The stock has a market capitalization of $4.78 million, a PE ratio of -0.22 and a beta of 1.21. Aclarion has a 1 year low of $1.54 and a 1 year high of $9.36. The company’s 50-day moving average is $2.24 and its 200-day moving average is $2.81.
Insider Transactions at Aclarion
In other Aclarion news, Director Ryan Bond acquired 21,122 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was acquired at an average cost of $2.37 per share, for a total transaction of $50,059.14. Following the completion of the transaction, the director directly owned 76,122 shares of the company’s stock, valued at $180,409.14. This represents a 38.40% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired 51,863 shares of company stock valued at $125,670 over the last 90 days. 0.01% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a research report on Tuesday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.50.
Check Out Our Latest Report on ACON
About Aclarion
Aclarion, Inc is a medical technology company focused on improving the diagnosis and treatment of chronic low back pain. The company develops data-driven tools intended to help physicians identify the spinal discs most likely to be contributing to a patient’s pain and support more informed treatment decisions.
Its principal product is Nociscan, a cloud-based software platform that analyzes magnetic resonance spectroscopy data from the spine. Using proprietary algorithms and chemical biomarkers associated with disc degeneration, Nociscan is designed to provide information about disc health and help distinguish potentially painful discs from discs that may not be the primary source of symptoms.
Aclarion’s technology is intended for use by spine specialists, radiologists and other healthcare providers as an adjunct to conventional imaging and clinical evaluation.
Featured Stories
- Five stocks we like better than Aclarion
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
